Development of a highly sensitive immunoassay based on pentameric nanobodies for carcinoembryonic antigen detection

Yi Gu,Yang Guo,Yang Deng,Haipeng Song,Rui Nian,Wenshuai Liu

DOI: https://doi.org/10.1016/j.aca.2023.341840

IF: 6.911

2023-10-02

Analytica Chimica Acta

Abstract:Background Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM-5) is a well-characterized biomarker for the clinical diagnosis of various cancers. Nanobodies, considered the smallest antibody fragments with intact antigen-binding capacity, have gained significant attention in disease diagnosis and therapy. Due to their peculiar properties, nanobodies have become promising alternative diagnostic reagents in immunoassay. However, nanobodies-based immunoassay is still hindered by small molecular size and low antigen capture efficacy. Therefore, there is a pressing need to develop novel nanobody-based immunoassays with superior performance. Results A novel pentameric nanobodies-based immunoassay (PNIA) was developed with enhanced sensitivity and specificity for CEACAM-5 detection. The binding epitopes of three anti-CEACAM-5 nanobodies (Nb1, Nb2 and Nb3) were analyzed. To enhance the capture and detection efficacy of CEACAM-5 in the immunoassay, we engineered bispecific nanobodies (Nb1–Nb2-rFc) as the capture antibody, and developed the FITC-labeled pentameric nanobodies (Nb3-VT1B) as the detection antibody. The binding affinities of Nb1–Nb2-rFc (1.746 × 10 −10 ) and Nb3-VT1B (1.279 × 10 −11 ) were significantly higher than those of unmodified nanobodies (Nb1-rFc, 4.063 × 10 −9 ; Nb2-rFc, 2.136 × 10 −8 ; Nb3, 3.357 × 10 −9 ). The PNIA showed a linear range of 0.625–160 ng mL −1 with a correlation coefficient R 2 of 0.9985, and a limit of detection of 0.52 ng mL −1 , which was 24-fold lower than the immunoassay using monomeric nanobody. The PNIA was validated with the spiked human serum. The average recoveries ranged from 91.8% to 102% and the coefficients of variation ranged from 0.026% to 0.082%. Significance and novelty The advantages of nanobodies offer a promising alternative to conventional antibodies in disease diagnosis. The novel PNIA demonstrated superior sensitivity and high specificity for the detection of CEACAM-5 antigen. This bispecific or multivalent nanobody design will provide some new insights into the design of immunoassays for clinical diagnosis.

chemistry, analytical